Analyst Naz Rahman from Maxim Group reiterated a Buy rating on Palisade Bio and keeping the price target at $2.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Naz Rahman has given his Buy rating due to a combination of factors including Palisade Bio’s recent financial activities and promising clinical trial results. The company reported a net loss for the second quarter of 2025 but has managed to secure additional funds through warrant exercises, which, combined with existing cash reserves, should support operations into the first quarter of 2026. This financial stability is a positive indicator for the company’s short-term viability.
Moreover, Palisade Bio has announced highly positive data from its Phase 1b trial of PALI-2108, particularly in moderate-to-severe ulcerative colitis patients, where all participants showed a clinical response. The company is strategically focusing on fibrostenotic Crohn’s disease, a market with limited competition and no FDA-approved therapies, which could provide a significant opportunity for growth. Plans to initiate further clinical trials and engage with the FDA in the first half of 2026 further reinforce the potential for future development and success, supporting the Buy rating.
According to TipRanks, Rahman is an analyst with an average return of -18.6% and a 28.30% success rate. Rahman covers the Healthcare sector, focusing on stocks such as Kazia Therapeutics, Palisade Bio, and Silexion Therapeutics.